MX2023007140A - Compuestos farmaceuticos. - Google Patents
Compuestos farmaceuticos.Info
- Publication number
- MX2023007140A MX2023007140A MX2023007140A MX2023007140A MX2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceutical compounds
- muscarinic
- agonists
- receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000017924 CHRM4 Human genes 0.000 abstract 2
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 abstract 2
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 abstract 2
- 101100107916 Xenopus laevis chrm4 gene Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se refiere a compuestos que son agonistas del receptor muscarínico M1 y M4 y que son útiles en el tratamiento de enfermedades mediadas por los receptores muscarínicos M1 y/o M4. También se proporcionan composiciones farmacéuticas que contienen los compuestos y los usos terapéuticos de los compuestos. Los compuestos proporcionados son de fórmula (1):(1) y sus sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020191.9A GB202020191D0 (en) | 2020-12-18 | 2020-12-18 | Pharmaceutical compounds |
| PCT/GB2021/053372 WO2022129951A1 (en) | 2020-12-18 | 2021-12-20 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007140A true MX2023007140A (es) | 2023-08-25 |
Family
ID=74221349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007140A MX2023007140A (es) | 2020-12-18 | 2021-12-20 | Compuestos farmaceuticos. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4263536A1 (es) |
| JP (1) | JP2024504252A (es) |
| KR (1) | KR20230121830A (es) |
| CN (1) | CN116848109A (es) |
| AU (1) | AU2021404194A1 (es) |
| CA (1) | CA3202054A1 (es) |
| CL (1) | CL2023001755A1 (es) |
| CO (1) | CO2023007838A2 (es) |
| CR (1) | CR20230256A (es) |
| DO (1) | DOP2023000125A (es) |
| EC (1) | ECSP23044370A (es) |
| GB (1) | GB202020191D0 (es) |
| IL (1) | IL303484A (es) |
| MX (1) | MX2023007140A (es) |
| PE (1) | PE20240646A1 (es) |
| WO (1) | WO2022129951A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2020
- 2020-12-18 GB GBGB2020191.9A patent/GB202020191D0/en not_active Ceased
-
2021
- 2021-12-20 JP JP2023536899A patent/JP2024504252A/ja active Pending
- 2021-12-20 IL IL303484A patent/IL303484A/en unknown
- 2021-12-20 MX MX2023007140A patent/MX2023007140A/es unknown
- 2021-12-20 KR KR1020237023911A patent/KR20230121830A/ko unknown
- 2021-12-20 CN CN202180093050.7A patent/CN116848109A/zh active Pending
- 2021-12-20 PE PE2023001903A patent/PE20240646A1/es unknown
- 2021-12-20 CR CR20230256A patent/CR20230256A/es unknown
- 2021-12-20 AU AU2021404194A patent/AU2021404194A1/en active Pending
- 2021-12-20 EP EP21836606.0A patent/EP4263536A1/en active Pending
- 2021-12-20 CA CA3202054A patent/CA3202054A1/en active Pending
- 2021-12-20 WO PCT/GB2021/053372 patent/WO2022129951A1/en active Application Filing
-
2023
- 2023-06-15 DO DO2023000125A patent/DOP2023000125A/es unknown
- 2023-06-15 EC ECSENADI202344370A patent/ECSP23044370A/es unknown
- 2023-06-15 CL CL2023001755A patent/CL2023001755A1/es unknown
- 2023-06-15 CO CONC2023/0007838A patent/CO2023007838A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3202054A1 (en) | 2022-06-23 |
| GB202020191D0 (en) | 2021-02-03 |
| JP2024504252A (ja) | 2024-01-31 |
| CN116848109A (zh) | 2023-10-03 |
| AU2021404194A1 (en) | 2023-08-03 |
| IL303484A (en) | 2023-08-01 |
| CR20230256A (es) | 2023-09-29 |
| CO2023007838A2 (es) | 2023-10-30 |
| KR20230121830A (ko) | 2023-08-21 |
| WO2022129951A1 (en) | 2022-06-23 |
| PE20240646A1 (es) | 2024-04-04 |
| DOP2023000125A (es) | 2023-08-31 |
| ECSP23044370A (es) | 2023-08-31 |
| US20220380379A1 (en) | 2022-12-01 |
| CL2023001755A1 (es) | 2024-01-05 |
| EP4263536A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007140A (es) | Compuestos farmaceuticos. | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| MX2021013941A (es) | Inhibidores del inflamasoma nlrp3. | |
| IN2014KN01075A (es) | ||
| HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX2009012579A (es) | Antagonistas piridil piperidina del receptor de orexina. | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| EP2037739A4 (en) | POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2021008510A (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina. | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| ZA202306305B (en) | Pharmaceutical compounds | |
| MX2012007006A (es) | Tiazoles biciclicos como moduladores alostericos de receptores mglur5. | |
| WO2024028458A3 (en) | Crystalline forms and salts of a muscarinic receptor agonist |